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Abstract Multiple myeloma (MM) is a plasma cell disorder
preceded by monoclonal gammopathy of undetermined
significance (MGUS). Incidence of MM and MGUS is higher
among patients with autoimmune disease. The aim of this
study was to determine whether a history of autoimmunity
has an impact on survival in MM and MGUS. Using high-
quality national Swedish registries, we identified 8367
patients with MM, 18,768 patients with MGUS, and
110,251 matched control subjects, and obtained information
on previous autoimmune disease in patients and controls. Cox
regression was used to calculate hazard ratios (HRs) for over-
all survival with 95 % confidence intervals (CIs). In patients
with MM and a prior autoimmune disease, the risk of death
was significantly increased, HR = 1.2 (95 % CI 1.2–1.3) com-
pared to MM patients with no history of autoimmunity. In
MGUS patients, a prior autoimmune disease was associated
with a significantly 1.4-fold elevated risk of death (95 % CI
1.3–1.4). When analyzing different types of autoimmune
diseases, a history of ulcerative colitis had a stronger impact
on survival inMM than in controls. Our findings that a history
of autoimmune disease has a negative impact on survival in
MM and MGUS could be due to shared underlying common
genetic factors, or that patients with a history of autoimmunity
develop more severe cases of MM and MGUS, or cumulative
comorbidity in the individual. Our results suggest that more
attention should be paid to comorbidity as a prognostic factor
in MGUS and MM, and underlines the need for studies aimed
at tailoring therapy according to comorbidity.
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Introduction
Multiple myeloma (MM) is a chronic plasma cell disorder,
characterized by a monoclonal proliferation of plasma cells
in the bone marrow coupled with an overproduction of mono-
clonal (M-) protein [1]. Clinical manifestations ofMM include
osteolytic lesions, anemia, renal failure, and hypercalcemia
[2]. Monoclonal gammopathy of undetermined significance
(MGUS) is an asymptomatic, pre-malignant condition with
an average risk of progression to MM or other lymphoprolif-
erative disorders of 1 % per year [3].
The etiology of MM and MGUS is largely unknown.
Familial risk factors have been identified, such as an increased
risk of MM and MGUS in first-degree relatives of patients
with these disorders [4–7]. This, together with ethnic dispar-
ities in the incidence patterns [8, 9], suggests a role for genetic
factors in the etiology. Furthermore, high age and male gender
have been found to be risk factors for MGUS, as have envi-
ronmental risk factors such as exposure to pesticides and
herbicides [10–12].
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Autoimmune diseases include a variety of conditions,
which jointly affect 5 to 10 % of the population [13].
Autoimmune diseases are characterized by increased activa-
tion of T or B cells toward own antigens (autoreactivity),
causing local or systemic symptoms [14]. A history of auto-
immunity increases the risk of certain malignancies [15–19],
possibly due to chronic stimulation of the immune system;
however, the complete underlying mechanisms are unknown.
We and several investigators have shown that a personal his-
tory of autoimmune disease is associated with a significantly
increased risk ofMGUS and to some extentMM [20–22]. Our
research group recently presented results showing a family
history of autoimmune disease to be associated with a signif-
icantly increased risk of MGUS [20], suggesting a common
genetic susceptibility between autoimmunity and plasma cell
disorders.
Autoimmune disease is a predictor of poor survival in the
general population, especially among women [23, 24]. A his-
tory of a few specific autoimmune diseases has been found to
increase mortality in patients with certain digestive tract can-
cers [17], but does not seem to influence prognosis in other
cancer types, e.g., lung cancer [18]. In a large study on patients
with Hodgkin lymphoma, a prior diagnosis of autoimmune
disease was associated with poorer survival [25]. In a smaller
study on Swedish MM patients, the effect of 33 different au-
toimmune diseases on survival was analyzed, and only a his-
tory of rheumatic fever was associated with a decreased sur-
vival, although results were limited due to small numbers [22].
To increase knowledge in this field, we conducted a
population-based study to determine whether a personal his-
tory of autoimmune disease has an impact on survival in MM
and MGUS.
Methods
Registries, patients, and control subjects
Patients in Sweden with MM are treated by physicians at
hospital-based hematology or oncology centers. All physi-
cians in Sweden are obliged to report each case of incident
cancer to the nationwide Swedish Cancer Register [26]. The
completeness and diagnostic accuracy of the register is high
(>93 %) for MM [27]. We identified all patients with a diag-
nosis of MM diagnosed from January 1, 2000, through
December 31, 2013, in the nationwide Swedish Cancer
Register. We established an MGUS cohort that has been de-
scribed previously [20] consisting ofMGUS patients retrieved
through a national network, as well as through the Swedish
Inpatient and Outpatient Registers, which have a high level of
coverage and accuracy [28, 29]. MGUS patients diagnosed
from January 1, 1988 through December 31, 2013 were
included.
For all included patients, we obtained information on
sex, date of birth, and date of diagnosis where the diag-
nosis was made. For MGUS patients, information on M-
protein type and concentration was collected, where this
was available. For each MM and MGUS patient, four
population-based control subjects matched by sex, year
of birth, and county of residence were chosen randomly
from the Swedish Register of Total Population database.
The control subjects had to be alive and free of any pre-
ceding hematologic malignancy at the time of MM or
MGUS diagnosis of the corresponding case.
We obtained information on occurrence and date of auto-
immune disease in patients and in controls from the Swedish
Inpatient Register from 1964 and onwards. The conditions
included in the analyses were equivalent to previously pub-
lished studies (Appendix 1) [20, 30].
Information on survival was gathered from the Swedish
Cause of Death Register. End of follow-up was December
31, 2013.
Statistical analysis
xWe used the Kaplan-Meier method with log-rank test and
regression models to compare outcome among patients and
controls with and without autoimmune disease. Specifically,
we calculated hazard ratios (HRs) and 95 % confidence inter-
vals (CIs) with Cox proportional hazards models that were
adjusted for age, year of diagnosis, and sex. In a sensitivity
analysis, each MM or MGUS case was paired with a control,
matching on age of diagnosis, and the risk for mortality was
calculated using Cox proportional hazards model as stated
above.
To avoid the possibility of autoimmune disease being
discovered more often in cases than in controls due to
the diagnostic work up of a plasma cell disorder, we
excluded all autoimmune disease diagnosed less than
1 year prior to diagnosis of MM or MGUS. In order to
investigate whether exposure time in addition to the pres-
ence of autoimmune disease had an impact on outcome,
we included the duration of exposure in a separate
model.
We performed analyses on seven specific autoimmune
diseases previously found to increase the risk of MM and/
or MGUS [20]; rheumatoid arthritis, pernicious anemia,
chronic rheumatic heart disease, ulcerative colitis,
polymyalgia rheumatica, giant cell arteritis, and psoriasis.
Among MGUS patients, we also performed analyses on
M-protein concentration (all isotypes combined) and by
M-protein isotype where IgM MGUS was analyzed sepa-
rately and IgG and IgA MGUS combined since IgM
MGUS and non-IgM MGUS appear to be clinically distinct
with regards to progression [31].
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Results
A total of 8367 patients with MM and 18,768 patients with
MGUS that were diagnosed from January 1, 2000 and from
January 1, 1988 through December 31, 2013, respectively,
were included in the study, as well as 33,577 matched control
subjects for MM and 76,674 matched control subjects for
MGUS (Table 1). The median age at diagnosis was 72 years
for both MM and MGUS patients.
A history of autoimmune disease was found in 1378
MM (16 %) patients and in 4380 MM controls (13 %).
Compared to MM patients with no history of autoimmune
disease, patients with MM and a prior history of autoim-
munity had a significantly increased risk of death
(HR = 1.2, 95 % CI 1.2–1.3). The increased risk was sim-
ilar in males (HR = 1.3, 95 % CI 1.1–1.4) and in females
(HR = 1.2, 95 % CI 1.1–1.3). Compared to controls with-
out prior autoimmune disease, MM controls with a history
of autoimmunity had a significantly increased risk of death
(HR = 1.8, 95 % CI 1.7–1.9) (Fig. 1, Table 2). In a sensi-
tivity analysis, we excluded all individuals with a previous
diagnosis of cancer, and found essentially the same results
(data not shown).
A history of autoimmune disease was found in 4032
MGUS (21 %) patients and in 9046 MGUS controls
(12 %). Compared to MGUS patients with no history of
autoimmune disease, patients with MGUS and a prior his-
tory of autoimmunity had a significantly increased risk of
death (HR = 1.4, 95 % CI 1.3–1.4). The results were the
same for both females and males. Compared to controls
without prior autoimmune disease, MGUS controls with
prior autoimmunity had a significantly increased risk of
death (HR = 1.7, 95 % CI 1.6–1.7) (Fig. 2, Table 2).
By a likelihood ratio test, the difference in effects of auto-
immune disease in MM and MGUS patients compared to that
in controls was statistically significant. The duration of expo-
sure to autoimmune disease did not have a significant effect on
survival when added to the model (p = 0.20 for MM and
p = 0.19 for MGUS, respectively).
In a sensitivity analysis, where mortality was compared
using age-matched MM or MGUS controls, the results were
almost identical (data not shown).
Analyses by specific autoimmune disease
Of the included MM patients, 151 had a prior history of
rheumatoid arthritis, 100 of pernicious anemia, 76 of chronic
rheumatic heart disease, 52 of ulcerative colitis, 223 of
polymyalgia rheumatica, 107 of psoriasis, and 58 of giant cell
arteritis.
The increased risk of dying after ulcerative colitis was
greater in MM patients (HR = 1.4, 95 % CI 1.0–1.9) than in
controls (HR = 1.2, 95 % CI 0.9–1.7). For the other specific
conditions analyzed, the excess mortality associated with a
prior autoimmune disease was not different, or was lower, in
MM patients compared to controls (Table 3).
Of the included MGUS patients, 665 had a prior history
of rheumatoid arthritis, 149 of pernicious anemia, 203 of
chronic rheumatic heart disease, 153 of ulcerative colitis,
817 of polymyalgia rheumatica, 336 of psoriasis, and 228
Table 1 Patient characteristics
MMa
patients
MM
controls
MGUSb
patients
MGUS
controls
Noc. in total 8367 33,577 18,768 76,674
Males no. (%) 4636 (55) 18,606 (55) 9765 (52) 39,928 (52)
Females no. (%) 3731 (45) 14,971 (45) 9003 (48) 36,746 (48)
Median age at diagnosis, years (range) 71 (31–97) 73 (30–101)
No. with AId (%) 1378 (16) 4380 (13) 4032 (21) 9046 (12)
Males (%) 688 (50) 2210 (51) 1990 (49) 4498 (50)
Females (%) 690 (50) 2170 (49) 2042 (51) 4548 (50)
Median age at diagnosis, years (range) 75 (32–98) 76 (31–101)
Median age at AI diagnosis, years
(range)
70 (16–97) 69 (7–97) 66 (10–96) 68 (10–99)
No. without AI (%) 6989 (84) 29,197 (87) 14,736 (79) 67,628 (88)
Males (%) 3948 (57) 16,396 (56) 7775 (53) 35,430 (52)
Females (%) 4202 (43) 12,801 (45) 8262 (47) 32,198 (47)
Median age at diagnosis, years (range) 70 (31–96) 71 (30–99)
aMM multiple myeloma
bMGUS monoclonal gammopathy of undetermined significance
cNo. number
dAI autoimmune disease
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of giant cell arteritis. For all conditions analyzed, the ex-
cess mortality added by a prior autoimmune disease was
lower in MGUS patients than the increased risk of dying in
controls with a prior autoimmune disease (Table 3).
Analyses on MGUS patients by M-protein isotype
and concentration
Information on M-protein isotype was available for 4210 in-
dividuals (22 %). The effect of a history of autoimmune dis-
ease on survival was not different between isotype IgA or IgG
and isotype IgM.
Information on M-protein concentration was available
for 3428 individuals (18 %). MGUS patients with a con-
centration of M-protein at diagnosis of 1.5 g/dL or more
had a significantly higher risk of death (HR = 1.2, 95 %
CI 1.0–1.4) compared to MGUS patients with a lower
M-protein concentration. The interaction between auto-
immune disease and concentration was not significant
(p = 0.28).
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Fig. 1 Survival in patients with multiple myeloma (MM), with and
without a personal history of autoimmune disease, compared to controls
with and without a personal history of autoimmune disease
Table 2 History of AI and
survival in MM and MGUS MM
a MGUSb
HRc 95 % CId HR 95 % CI
Females
Groups: MM/MGUS + AIe vs. MM/MGUS
+ no AI
No. deaths/subjects in each group:
1.2
462/690
1947/3041
1.1–1.3 1.4
936/2042
3415/6961
1.3–1.5
Controls + AI vs. controls + no AI
No. deaths/subjects in each group:
1.9
719/2170
2679 /12,801
1.7–2.0 1.7
1722/4548
11,239/32,198
1.6–1.8
Males
MM/MGUS + AI vs. MM/MGUS + no AI
No. deaths/subjects in each group:
1.3
448/688
2471/3948
1.1–1.4 1.4
950/1990
4199/7775
1.3–1.5
Controls + AI vs. controls + no AI
No. deaths/subjects in each group:
1.8
811/2210
3903/16,396
1.6–1.9 1.6
1878/4498
13,798/35,430
1.6–1.7
Overall
MM/MGUS + AI vs. MM/MGUS + no AI
No. deaths/subjects in each group:
1.2
910/1378
4418/6989
1.2–1.3 1.4
1886 /4032
7614/14,736
1.3–1.4
Controls + AI vs. controls + no AI
No. deaths/subjects in each group:
1.8
1530 /4380
6582/29,197
1.7–1.9 1.7
3600/9046
25,037/67,628
1.6–1.7
aMM multiple myeloma
bMGUS monoclonal gammopathy of undetermined significance
cHR hazard ratio
dCI confidence interval
eAI autoimmune disease
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Discussion
In this large population-based study including over 8000 MM
patients, almost 19,000 MGUS patients, and their 110,000
matched control subjects, we found that a history of autoim-
mune disease was associated with a reduced survival in MM
and MGUS patients. Furthermore, although based on smaller
numbers, ulcerative colitis had a greater impact onmortality in
MM than other autoimmune conditions. These novel findings
suggest a more aggressive disease course in autoimmunity-
associated plasma cell disorders and that more attention
should be paid to comorbidity when predicting prognosis
and tailoring therapy.
The finding that autoimmune disease is a predictor of
worse survival in MM patients is an important finding, and
contradicts results from a previous smaller study on autoim-
mune disease and MM survival where no effect on survival in
MM was observed [22]. However, the abovementioned study
was a cohort study on individuals with autoimmune disease,
and captured only 457 cases of multiple myeloma. Our find-
ings are consistent with autoimmune disorders being a predic-
tor of poor survival in the population [23, 24], and expand on
previous investigations showing autoimmune disease to have
negative impact on survival in Hodgkin lymphoma and in
certain digestive tract cancers [17, 25]. The intensity of med-
ical treatments for MM patients requires careful consideration
of risks and benefits, particularly if there are other co-existing
serious illnesses. With an aging population, the number of
MM patients has grown and will continue to grow in the years
to come [32]. In MM patients, comorbid diseases may in-
crease the risk of treatment-related complications. Also, MM
itself or its treatment may aggravate existing comorbid dis-
eases, leading to lower performance status, decreased quality
of life, and a shorter overall survival [33]. Despite the impor-
tance of considering comorbid diseases in the treatment and
prognosis of MM, the literature on comorbidities in MM is
limited and based on small series [34–38]. In these studies,
survival is negatively influenced by increasing number of co-
morbid conditions. Approximately 80% ofMM patients have
one or more comorbid conditions, and almost half have two or
more [34–36]. There are few clinical trials where the elderly
frail patients are included [39]; therefore, population-based
studies are a valuable tool to estimate survival in a diverse
MM population [32, 40–43].
In patients with MGUS, a history of autoimmune disease
and its impact on survival have, to our knowledge, not been
investigated previously. We found that MGUS patients with
previous autoimmune disease had a significantly 1.4-fold in-
creased risk of death. In patients with MGUS, the effect of a
history of autoimmune disease on survival was not affected by
isotype or by M-protein concentration at MGUS diagnosis.
Previous investigators of cancer survival after autoimmune
diseases have speculated that the underlying explanation
may be poorer performance status or non-tolerance of therapy.
However, this does not explain the decreased survival after
autoimmune diseases in MGUS patients, who are asymptom-
atic by definition and do not receive therapy. Our findings of
an increased risk of death in MGUS patients with a history of
autoimmune disease thus suggest an unknown underlying
factor which may impact the risk of death in MGUS patients
with a prior autoimmune disease, and could also potentially
shed light on the pathogenesis of MGUS. In addition, whether
a prior autoimmune disease is also a risk factor for progression
in MGUS needs to be clarified.
Considering autoimmune diseases are known to be more
common in females than in males, we explored survival out-
comes by sex to see if autoimmunity might be associated with
different survival patterns for male and female patients with
MM or MGUS; however, they were not.
Interestingly, a history of ulcerative colitis had a greater
impact on survival in MM patients than a history of ulcerative
colitis had in the general population, although the confidence
intervals overlapped so the difference was not statistically
significant. It is possible that therapy-related factors might
have played a role. Another possibility is that individuals de-
veloping MM after ulcerative colitis are more likely to harbor
additional poor prognostic factors.
Our study has several strengths, such as its large size and
high-quality data from Sweden. The data is derived from a
stable population with access to standardized medical health
care during the entire study period, ensuring a generalizability
of findings. The large study size has generated a high power,
as shown in the narrow confidence intervals. Recall bias was
ruled out due to the study design using nationwide registers.
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Fig. 2 Survival in patients with monoclonal gammopathy of
undetermined significance (MGUS), with and without a personal history
of autoimmune disease, compared to controls with and without a personal
history of autoimmune disease
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Because of the large study size, patient-related information
was only gathered through registers, and we were not able to
validate individual medical records, and we did not have in-
formation on established risk factors such as genetic aberra-
tions detectable by fluorescence in situ hybridization (FISH),
both of which are limitations of our study. Also, this is a
hypothesis-generating study, including many autoimmune
diseases, and the findings on specific autoimmune diseases
should be interpreted with caution. In our study, individuals
with a history of autoimmune disease were older than those
without. However, analyses were adjusted for age, and a sen-
sitivity analysis where mortality was compared between cases
and age-matched controls showed almost identical results.
Thus, the age difference is unlikely to explain the difference
in survival. The results for MGUS are cohort-based, and
although large, it does not necessarily represent the true pop-
ulation since MGUS is an asymptomatic condition and the
cohort was clinically based, not a screened population. The
use of inpatient data could have led to under-ascertainment of
less severe forms of autoimmune diseases. Importantly, the
Table 3 History of specific
autoimmune conditions and
survival in MM and MGUS
(both genders)
MMa MGUSb
No. of MM
patients
with AIc (%)
HRd 95 % CIe No. of MGUS
patients with
AI (%)
HR 95 % CI
Rheumatoid arthritis 151 (1.8) 665 (3.5)
MM/MGUS + AI vs. MM/
MGUS + no AI
100/151 1.3 1.0–1.6 322/665 1.3 1.2–1.5
Controls + AI vs. controls
+ no AI
182/515 1.8 1.6–2.1 545/1334 1.8 1.7–2.0
Pernicious anemia 100 (1.2) 149 (0.8)
MM/MGUS + AI vs. MM/
MGUS + no AI
70/100 1.2 1.0–1.5 90/149 1.5 1.2–1.9
Controls + AI vs. controls
+ no AI
62/127 2.1 1.7–2.7 211/328 2.0 1.7–2.3
Chronic rheumatic heart
disease
76 (0.9) 203 (0.1)
MM/MGUS + AI vs. MM/
MGUS + no AI
41/76 0.9 0.7–1.3 86/203 1.4 1.1–1.7
Controls + AI vs. controls
+ no AI
78/305 1.6 1.3–2.0 193/599 2.0 1.8–2.4
Ulcerative colitis 52 (0.6) 153 (0.8)
MM/MGUS + AI vs. MM/
MGUS + no AI
33/52 1.4 1.0–1.9 47/153 1.1 0.8–1.5
Controls + AI vs. controls
+ no AI
38/191 1.2 0.9–1.7 87/327 1.6 1.3–2.0
Polymyalgia rheumatica 223 (2.7) 817 (4.4)
MM/MGUS + AI vs. MM/
MGUS + no AI
146/223 1.0 0.8–1.2 343/817 1.0 0.9–1.2
Controls + AI vs. controls
+ no AI
227/603 1.5 1.4–1.8 600/1410 1.3 1.2–1.5
Giant cell arteritis 58 (0.7) 228 (1.2)
MM/MGUS + AI vs. MM/
MGUS + no AI
38/58 0.8 0.6–1.1 92/228 1.0 0.8–1.2
Controls + AI vs. controls
+ no AI
53/150 1.4 1.1–1.8 141/300 1.4 1.1–1.6
Psoriasis 107 (1.3) 336 (1.8)
MM/MGUS + AI vs. MM/
MGUS + no AI
51/107 0.9 0.7–1.2 103/336 1.3 1.0–1.6
Controls + AI vs. controls
+ no AI
98/507 1.3 1.1–1.6 203/824 1.4 1.2–1.6
aMM multiple myeloma
bMGUS monoclonal gammopathy of undetermined significance
cAI autoimmune disease
dHR hazard ratio
eCI confidence interval
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autoimmune disease did not have to be the reason for admis-
sion, so all patients with autoimmune disease admitted for any
reasons are included in our analysis. The prevalence of auto-
immune disease was higher inMM (16 %) andMGUS (21 %)
patients than in controls (12–13 %), which is consistent with
previous findings of a significantly increased risk of MGUS
and to some extent MM after autoimmune disease [20–22].
The overall high prevalence of autoimmunity in our study is
surprising; however, a wide range of autoimmune disorders
were included (Appendix 1) and although we were not able to
validate individual medical records, since history of autoim-
mune diseases was assessed in the same way among MM and
MGUS patients and matched controls, any under- or over-
diagnosis should be non-differential.
In conclusion, our findings that a personal history of auto-
immune disease has a negative impact on survival in MM and
MGUS patients could be due to underlying common genetic
factors, or that patients with a personal history of autoimmu-
nity develop more severe forms of MM or MGUS as a result
of either the autoimmune disease or its treatment, or cumula-
tive comorbidity in the individual. Our findings suggest that
more attention should be paid to comorbidity, such as autoim-
mune disease, as a prognostic factor in MM, and perhaps also
in MGUS. Treatment options for MM are investigated today
in randomized clinical trials which are subject to selection bias
with strict inclusion and exclusion criteria, often with omis-
sion of elderly patients and patients with comorbidites.
However, a majority of MM patients suffer from multiple
other diseases, which may both affect survival and make
patients unsuitable for certain treatments. Our findings raise
interesting questions on the pathogenesis ofMGUS, and high-
light the importance of accounting for comorbidities such as
autoimmune disease both for predicting prognosis and for
tailoring therapy in patients with plasma cell dyscrasias.
Acknowledgments This research was supported by grants from the
Swedish Blodcancerfonden, the Swedish Cancer Society, the regional
agreement on medical training and clinical research (ALF) between
Stockholm County Council and Karolinska Institutet, the Karolinska
Institutet Foundations, the University of Iceland Research Fund,
Icelandic Centre for Research (RANNIS), and Landspitali University
Hospital research Fund.
Authorship contributions SYK, EKL, MH, and SHL designed the
study. SYK, OL, and IT obtained data. SHL performed the analyses.
EKL and SYK wrote the report. All the authors were involved in the
analyses and the interpretation of the results. All authors read, gave com-
ments, and approved the final version of the manuscript. All the authors
had full access to the data in the study and take responsibility for the
integrity of the data and the accuracy of the data analysis.
Compliance with ethical standards This study was approved by the
Regional Ethical Review Board in Stockholm.
Conflict of interest The authors declare that they have no conflict of
interest.
Appendix
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Swerdlov S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, Thiele J,
Vardiman J (2008) WHO Classification of Tumours of
Haematopoietic and Lymphoid Tissues, 4th edn. IARC, Lyon
2. Kyle RA, GertzMA,Witzig TE, Lust JA, LacyMQ, Dispenzieri A,
Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME,
Therneau TM, Greipp PR (2003) Review of 1027 patients with
newly diagnosed multiple myeloma. Mayo Clin Proc 78:21–33
3. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR,
Plevak MF, Melton LJ 3rd (2002) A long-term study of prognosis
in monoclonal gammopathy of undetermined significance. N Engl J
Med 346:564–569
4. Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR,
Colby CL, Phelps TK, Dispenzieri A, Kumar SK, Katzmann JA,
Rajkumar SV (2009) Increased risk of monoclonal gammopathy in
first-degree relatives of patients with multiple myeloma or mono-
clonal gammopathy of undetermined significance; Blood. United
States 114:785–790
5. Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K,
Goldin LR (2006) Familial characteristics of autoimmune and
Table 4 Autoimmune conditions included in the study
Rheumatoid arthritis Lupoid hepatitis
Systemic sclerosis Celiac disease
Sjögren’s syndrome Granulomatosis with polyangiitis
(Wegener’s)
Systemic lupus erythematosus Dressler syndrome
Polymyositis or dermatomyositis Chronic rheumatic heart disease
Hashimoto thyroiditis Multiple sclerosis
Grave’s disease Amyotrophic lateral sclerosis
Addison disease Rheumatic fever
Pernicious anemia Sarcoidosis
Autoimmune hemolytic anemia Reiter disease
Immune thrombocytopenia Crohn disease
Primary biliary cirrhosis Ulcerative colitis
Discoid lupus erythematosus Ankylosing spondylitis
Localized scleroderma Polymyalgia rheumatica
Myasthenia gravis Psoriasis
Autoimmune hepatitis Behcet disease
Polyarteritis nodosa Giant cell arteritis
Guillain-Barré syndrome Vitiligo
Diabetes type 1 Aplastic anemia
Ann Hematol (2017) 96:261–269 267
hematologic disorders in 8,406 multiple myeloma patients: a
population-based case-control study. Int J Cancer 118:3095–3098
6. Landgren O, Kristinsson SY, Goldin LR, Caporaso NE, Blimark C,
Mellqvist UH, Wahlin A, Bjorkholm M, Turesson I (2009) Risk of
plasma cell and lymphoproliferative disorders among 14621 first-
degree relatives of 4458 patients with monoclonal gammopathy of
undetermined significance in Sweden. Blood 114:791–795
7. Kristinsson SY, Bjorkholm M, Goldin LR, Blimark C, Mellqvist
UH, Wahlin A, Turesson I, Landgren O (2009) Patterns of hemato-
logic malignancies and solid tumors among 37,838 first-degree
relatives of 13,896 patients with multiple myeloma in Sweden. Int
J Cancer 125:2147–2150
8. LandgrenO,Weiss BM (2009) Patterns of monoclonal gammopathy
of undetermined significance and multiple myeloma in various
ethnic/racial groups: support for genetic factors in pathogenesis.
Leukemia 23:1691–1697
9. Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR,
Baris D, Fears TR, Hoover RN, Linet MS (2006) Risk of monoclo-
nal gammopathy of undetermined significance (MGUS) and sub-
sequent multiple myeloma among African American and white
veterans in the United States. Blood 107:904–906
10. Landgren O, Kyle RA, Hoppin JA, Beane Freeman LE, Cerhan JR,
Katzmann JA, Rajkumar SV, Alavanja MC (2009) Pesticide expo-
sure and risk of monoclonal gammopathy of undetermined signif-
icance in the Agricultural Health Study. Blood 113:6386–6391
11. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF,
Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd (2006)
Prevalence of monoclonal gammopathy of undetermined signifi-
cance. N Engl J Med 354:1362–1369
12. Landgren O, ShimYK,Michalek J, Costello R, Burton D,Ketchum
N, Calvo KR, Caporaso N, Raveche E,Middleton D,Marti G, Vogt
RF Jr (2015) Agent orange exposure and monoclonal gammopathy
of undetermined significance: an Operation Ranch Hand Veteran
Cohort Study. JAMA Oncol 1:1061–1068
13. Forabosco P, Bouzigon E, Ng MY, Hermanowski J, Fisher SA,
Criswell LA, Lewis CM (2009) Meta-analysis of genome-wide
linkage studies across autoimmune diseases. Eur J Hum Genet 17:
236–243
14. Zhernakova A, van Diemen CC, Wijmenga C (2009) Detecting
shared pathogenesis from the shared genetics of immune-related
diseases. Nat Rev Genet 10:43–55
15. Goldin LR, Landgren O (2009) Autoimmunity and lymphomagen-
esis. Int J Cancer 124:1497–1502
16. Landgren AM, Landgren O, Gridley G, Dores GM, Linet MS,
Morton LM (2011) Autoimmune disease and subsequent risk of
developing alimentary tract cancers among 4.5 million US male
veterans. Cancer 117:1163–1171
17. Hemminki K, Liu X, Ji J, Sundquist J, Sundquist K (2012) Effect of
autoimmune diseases on mortality and survival in subsequent di-
gestive tract cancers. Ann Oncol 23:2179–2184
18. Hemminki K, Liu X, Ji J, Sundquist J, Sundquist K (2012) Effect of
autoimmune diseases on risk and survival in histology-specific lung
cancer. Eur Respir J 40:1489–1495
19. Hemminki K, Liu X, Ji J, Sundquist J, Sundquist K (2012) Kaposi
sarcoma and Merkel cell carcinoma after autoimmune disease. Int J
Cancer 131:E326–E328
20. Lindqvist EK, Goldin LR, Landgren O, Blimark C, Mellqvist UH,
Turesson I, Wahlin A, Bjorkholm M, Kristinsson SY (2011)
Personal and family history of immune-related conditions increase
the risk of plasma cell disorders: a population-based study. Blood
118:6284–6291
21. Brown LM, Gridley G, Check D, Landgren O (2008) Risk of mul-
tiple myeloma and monoclonal gammopathy of undetermined sig-
nificance among white and black male United States veterans with
prior autoimmune, infectious, inflammatory, and allergic disorders.
Blood 111:3388–3394
22. Hemminki K, Liu X, Forsti A, Ji J, Sundquist J, Sundquist K (2012)
Effect of autoimmune diseases on incidence and survival in subse-
quent multiple myeloma. J Hematol Oncol 5:59
23. Walsh SJ, Rau LM (2000) Autoimmune diseases: a leading cause of
death among young and middle-aged women in the United States.
Am J Public Health 90:1463–1466
24. Thomas SL, Griffiths C, Smeeth L, Rooney C, Hall AJ (2010)
Burden of mortality associated with autoimmune diseases
among females in the United Kingdom. Am J Public Health
100:2279–2287
25. Landgren O, Pfeiffer RM, Kristinsson SY, Bjorkholm M (2010)
Survival patterns in patients with Hodgkin’s lymphoma with a
pre-existing hospital discharge diagnosis of autoimmune disease.
J Clin Oncol 28:5081–5087
26. Swedish National Board of Health and Welfare. Svenska
cancerregistret. Socialstyrelsen, Stockholm, Sweden
27. Turesson I, Linet MS, Bjorkholm M, Kristinsson SY, Goldin LR,
Caporaso NE, Landgren O (2007) Ascertainment and diagnostic
accuracy for hematopoietic lymphoproliferative malignancies in
Sweden 1964-2003. Int J Cancer 121:2260–2266
28. Nilsson A, Spetz C, Carsjo K, Nightingale R, Smedby B (1994)
Slutenvårdsregistrets tillförlitlighet. Lakartidningen 91:598–605
29. Swedish National Board of Health and Welfare. Patientregistret.
Socialstyrelsen, Stockholm, Sweden
30. Kristinsson SY, Koshiol J, Bjorkholm M, Goldin LR, McMaster
ML, Turesson I, Landgren O (2010) Immune-related and in-
flammatory conditions and risk of lymphoplasmacytic lympho-
ma or Waldenstrom macroglobulinemia. J Natl Cancer Inst 102:
557–567
31. Rajkumar SV, Kyle RA, Buadi FK (2010) Advances in the diagno-
sis, classification, risk stratification, and management of monoclo-
nal gammopathy of undetermined significance: implications for
recategorizing disease entities in the presence of evolving scientific
evidence. Mayo Clin Proc 85:945–948
32. Turesson I, Velez R, Kristinsson SY, Landgren O (2010) Patterns of
multiple myeloma during the past 5 decades: stable incidence rates
for all age groups in the population but rapidly changing age distri-
bution in the clinic. Mayo Clin Proc 85:225–230
33. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J,
Mateos MV, Rosinol L, Boccadoro M, Cavo M, Lokhorst H,
Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P,
Gramatzki M, Hajek R, Johnsen HE, Leal Da Costa F, Sezer O,
Spencer A, Beksac M, Morgan G, Einsele H, San Miguel JF,
Sonneveld P (2011) Personalized therapy in multiple myeloma ac-
cording to patient age and vulnerability: a report of the European
Myeloma Network (EMN). Blood 118:4519–4529
34. Kleber M, Ihorst G, Gross B, Koch B, Reinhardt H, Wasch R,
Engelhardt M (2013) Validation of the Freiburg comorbidity index
in 466 multiple myeloma patients and combination with the inter-
national staging system are highly predictive for outcome. Clin
Lymphoma Myeloma Leuk 3(5):541–551
35. Kleber M, Ihorst G, Terhorst M, Koch B, Deschler B, Wasch R,
Engelhardt M (2011) Comorbidity as a prognostic variable in
multiple myeloma: comparative evaluation of common comor-
bidity scores and use of a novel MM-comorbidity score. Blood
Cancer J 1:e35
36. Offidani M, Corvatta L, Polloni C, Centurioni R, Visani G,
Brunori M, Gentili S, Catarini M, Samori A, Blasi N, Alesiani
F, Caraffa P, Burattini M, Galieni P, Fraticelli P, Ferranti M,
Giuliodori L, Leoni P (2012) Assessment of vulnerability mea-
sures and their effect on survival in a real-life population of
multiple myeloma patients registered at Marche Region
Multiple Myeloma Registry. Clin Lymphoma Myeloma Leuk
12:423–432
37. KleberM, Ihorst G, Deschler B, Jakob C, Liebisch P, Koch B, Sezer
O, Engelhardt M (2009) Detection of renal impairment as one
268 Ann Hematol (2017) 96:261–269
specific comorbidity factor in multiple myeloma: multicenter study
in 198 consecutive patients. Eur J Haematol 83:519–527
38. Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M,
Fanin R, Boccadoro M, Corradini P (2009) The hematopoietic
cell transplantation comorbidity index (HCT-CI) predicts clini-
cal outcomes in lymphoma and myeloma patients after reduced-
intensity or non-myeloablative allogeneic stem cell transplanta-
tion. Leukemia 23:1131–1138
39. Falco P, Cavallo F, Larocca A, Rossi D, Guglielmelli T, Rocci A,
Grasso M, Siez ML, De Paoli L, Oliva S, Molica S, Mina R, Gay F,
Benevolo G, Musto P, Omede P, Freilone R, Bringhen S, Carella
AM, Gaidano G, Boccadoro M, Palumbo A (2013) Lenalidomide-
prednisone induction followed by lenalidomide-melphalan-
prednisone consolidation and lenalidomide-prednisone mainte-
nance in newly diagnosed elderly unfit myeloma patients.
Leukemia 27:695–701
40. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm
M (2007) Patterns of survival in multiple myeloma: a population-
based study of patients diagnosed in Sweden from 1973 to 2003. J
Clin Oncol 25:1993–1999
41. Turesson I, Velez R, Kristinsson SY, Landgren O (2010) Patterns of
improved survival in patients with multiple myeloma in the
twenty-first century: a population-based study. J Clin Oncol
28:830–834
42. Kumar SK, Dispenzieri A, LacyMQ,GertzMA, Buadi FK, Pandey
S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A,
Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2013)
Continued improvement in survival in multiple myeloma: changes
in early mortality and outcomes in older patients. Leukemia 28(5):
1122–1128
43. Kristinsson SY, Anderson WF, Landgren O (2014) Improved long-
term survival in multiple myeloma up to the age of 80 years.
Leukemia 28(6):1346
Ann Hematol (2017) 96:261–269 269
